Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarkers and kits for diagnosis of liver fibrosis and cirrhosis and use method

A technology of biomarkers and diagnostic kits, applied in measurement devices, instruments, scientific instruments, etc., can solve problems affecting the early detection and treatment of liver fibrosis

Pending Publication Date: 2018-12-21
HUMAN METABOLOMICS INST INC
View PDF10 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no rapid and efficient diagnostic kit for liver fibrosis on the market, which seriously affects the early detection and treatment of liver fibrosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers and kits for diagnosis of liver fibrosis and cirrhosis and use method
  • Biomarkers and kits for diagnosis of liver fibrosis and cirrhosis and use method
  • Biomarkers and kits for diagnosis of liver fibrosis and cirrhosis and use method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1: Screening of differential biomarkers

[0053] The design method of this experiment can be found in the appendix figure 1 . The test samples in the present invention were approved by the local ethics committee and informed consent was obtained from all subjects. The present invention enrolls 1374 subjects in total, which are divided into training set, test set and independent verification set. In the training set and test set, ultra-high performance liquid chromatography tandem mass spectrometry was used to detect fasting (12 hours) serum samples from 502 healthy people and 504 patients with different degrees of chronic liver disease caused by HBV infection confirmed by liver biopsy. The content of metabolites such as bile acid and amino acid, and the detection of corresponding clinical indicators. In an independent validation set, the content of bile acid and amino acid metabolites in fasting (12 hours) serum samples from 368 patients with chronic liver ...

Embodiment 2

[0120] Example 2 biomarker combination (elaidic acid (C18:2n6t), taurocholate (TCA), tyrosine (Tyrosine) and valine predictive power

[0121] Samples and data sources are the same as in Example 1.

[0122]The random forest model was used to evaluate candidate variables and establish a model to verify the combination of elaidic acid (C18:2n6t), taurocholate (TCA), tyrosine (Tyrosine) and valine in predicting the degree of liver fibrosis The prediction ability, the results are shown in Table 4. It can be seen from Table 4 that the combination of these four metabolites has better predictive ability compared with the existing test indicators.

[0123] The random forest model is carried out by using the LiveForest software of Shenzhen Huiyun Biotechnology Co., Ltd., the software copyright registration number is 2018SR227394, and the software name: a machine learning diagnosis system for chronic liver disease based on metabolomics V1.0.

[0124] Table 4

[0125]

[0126] ...

Embodiment 3

[0128] Example 3: Biomarker Combination Random Forest Model Differentiates Healthy and Chronic Liver Disease Groups

[0129] The selected biomarkers are: TCA (taurocholate), Tyrosine (tyrosine), and age, AST, ALT and platelets are as described in Example 1, and 363 patients with chronic liver disease and 371 healthy individuals were in the training set Humans, 141 patients with chronic liver disease and 131 healthy people in the test set, using the biomarker combination random forest model trained in the training set, the possibility of the above subjects suffering from chronic liver disease can be output, and through the ROC analysis Youden's optimal point finds the optimal cutoff value that assesses the model's overall ability to distinguish sick from healthy individuals. result( figure 2 ): The area under the ROC curve and the 95% confidence interval in the training set are 0.986 (0.979-0.991), the area under the PR curve and the 95% confidence interval are 0.988 (0.983...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a group of biomarkers which can be used for detecting liver fibrosis and cirrhosis. The biomarkers refer to metabolite components existing in a biological sample of a subject body and comprise a plurality of metabolites, wherein the metabolites are selected from cholic acid, amino acid and fatty acid. Metabolite combination comprises at least one amino acid, fatty acid and cholic acid, the metabolite combination is differentially expressed in at least one target plasma or serum and in a control plasma or serum. The biomarkers can optionally be combined with clinical indicators for diagnosis of liver fibrosis in the subject body. The biomarker composition has the characteristics of high sensitivity and specificity for pathological staging diagnosis of liver fibrosis patients, and can be clinically applied as a non-invasive means to improve clinical diagnosis and reduce puncture pain of the patients. The invention further provides a use method of the biomarkers andkits containing the biomarkers.

Description

technical field [0001] The invention belongs to the technical field of biological detection, in particular to the field of biomarkers and kits for the diagnosis and detection of liver fibrosis and liver cirrhosis. Background technique [0002] Cirrhosis and Hepatocellular Carcinoma are very serious liver diseases, and Hepatic Fibrosis is an early stage of their development. Hepatic fibrosis is a disease of diffuse excessive deposition of extracellular matrix (ECM) in the liver, which is characterized by increased levels of intrahepatic fibrogenesis (i.e., massive deposition of ECM) and fibrolysis (i.e., degradation of ECM). ) insufficient [Tacke F, Weiskirchen R. Update on hepatic stellate cells: pathogenic role inliver fibrosis and novel isolation techniques. Expert Review of Gastroenterology & Hepatology. 2012, 6:67–80.]. Liver fibrosis is a common and common pathological outcome of many liver diseases, especially various chronic liver diseases, and its formation and deve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/06
CPCG01N30/02G01N30/06
Inventor 贾伟谢国祥卫润民王京晔
Owner HUMAN METABOLOMICS INST INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com